Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Olympus, Carl Zeiss Sign Patent Deal

By Drug Discovery Trends Editor | July 12, 2012

Olympus America Inc. and Carl Zeiss Microscopy GmbH, Jena, Germany, have signed a nonexclusive worldwide licensing agreement allowing Zeiss to access an extensive portfolio of patents held by Olympus in the field of digital pathology and virtual microscopy. The patents included in the licensing deal cover methods and equipment for creating, storing and delivering virtual microscopy slides. The technology enables individuals to view and share high-resolution virtual microscopy images over the Internet.

“Global adoption of digital slide scanning continues to expand into new medical and scientific applications,” said Brad Burklow, Executive Director Business Development, Scientific Equipment Group, Olympus Corporation of the Americas. “Olympus is the holder of many important patents in this area, and we feel it is vital to allow broadaccess to these technologies in order to advance the field of pathology andmedical research. We are confident that leveraging these technologies will enhance healthcare for patients around the world.”

“The handling of digital data has become a major driver of the development of modern microscopy,” said Dr. Bernhard Ohnesorge, Member of the Board and General Manager BioSciences Division of Carl Zeiss Microscopy. “Integrating the virtual slide functionality into our research microscope systems will enable our customers to become more efficient and to explore new scientific approaches. This will help them to better understand the root causes of the most challenging diseases.”

The companies are not making specific terms and conditions of the agreement public.

Date: July 12, 2012
Source: Olympus America Inc., Carl Zeiss Microscopy GmbH

 

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE